We’ve recently updated our valuation analysis.

bluebird bio Valuation

Is BLUE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLUE?

Other financial metrics that can be useful for relative valuation.

BLUE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue149.4x
Enterprise Value/EBITDA-1.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does BLUE's PB Ratio compare to its peers?

The above table shows the PB ratio for BLUE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.7x
HUMA Humacyte
2.7x-20.2%US$323.8m
TSVT 2seventy bio
1.8x26.6%US$579.4m
MRSN Mersana Therapeutics
7.5x10.2%US$675.5m
ENTA Enanta Pharmaceuticals
2.9x58.7%US$928.0m
BLUE bluebird bio
4x39.1%US$630.9m

Price-To-Book vs Peers: BLUE is expensive based on its Price-To-Book Ratio (4x) compared to the peer average (3.7x).


Price to Earnings Ratio vs Industry

How does BLUE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
n/an/an/a

Price-To-Book vs Industry: BLUE is expensive based on its Price-To-Book Ratio (4x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is BLUE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLUE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BLUE's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BLUE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BLUE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BLUE's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BLUE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.61
US$7.33
-3.6%
30.2%US$10.00US$3.00n/a9
Nov ’23US$6.35
US$7.56
+19.0%
31.3%US$10.00US$3.00n/a9
Oct ’23US$6.33
US$7.78
+22.9%
31.9%US$10.00US$3.00n/a9
Sep ’23US$6.55
US$7.33
+12.0%
34.0%US$10.00US$3.00n/a9
Aug ’23US$3.75
US$7.40
+97.3%
48.4%US$14.00US$2.00n/a10
Jul ’23US$4.28
US$7.33
+71.3%
51.4%US$14.00US$2.00n/a9
Jun ’23US$2.97
US$7.33
+146.9%
51.4%US$14.00US$2.00n/a9
May ’23US$3.63
US$7.89
+117.3%
42.0%US$14.00US$3.00n/a9
Apr ’23US$4.96
US$9.70
+95.6%
62.2%US$25.00US$3.00n/a10
Mar ’23US$5.62
US$12.55
+123.2%
35.9%US$25.00US$6.00n/a11
Feb ’23US$7.80
US$12.55
+60.8%
35.9%US$25.00US$6.00n/a11
Jan ’23US$9.99
US$13.31
+33.2%
28.2%US$25.00US$9.00n/a13
Dec ’22US$10.05
US$13.62
+35.5%
27.9%US$25.00US$9.00US$7.6113
Nov ’22US$24.23
US$22.80
-5.9%
19.3%US$37.00US$18.00US$6.3515
Oct ’22US$19.13
US$22.80
+19.2%
19.3%US$37.00US$18.00US$6.3315
Sep ’22US$18.32
US$24.53
+33.9%
29.2%US$45.00US$18.00US$6.5515
Aug ’22US$25.41
US$46.47
+82.9%
37.3%US$86.00US$27.00US$3.7515
Jul ’22US$32.42
US$46.80
+44.4%
37.5%US$86.00US$27.00US$4.2815
Jun ’22US$31.11
US$48.67
+56.4%
36.5%US$86.00US$27.00US$2.9715
May ’22US$30.00
US$48.93
+63.1%
37.2%US$86.00US$27.00US$3.6315
Apr ’22US$30.04
US$47.89
+59.4%
34.8%US$86.00US$27.00US$4.9618
Mar ’22US$30.08
US$44.28
+47.2%
36.7%US$86.00US$26.00US$5.6218
Feb ’22US$45.74
US$78.79
+72.3%
30.6%US$146.00US$48.00US$7.8019
Jan ’22US$43.27
US$79.37
+83.4%
30.3%US$146.00US$48.00US$9.9919
Dec ’21US$45.87
US$80.05
+74.5%
29.2%US$146.00US$50.00US$10.0520

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies